InMed Pharmaceuticals (INM) shares were up more than 200% pre-bell Monday following a muted session.
Vera Therapeutics (VERA) shares were 75% higher after the company said its phase 3 trial of atacicept for the treatment of immunoglobulin A nephropathy achieved its primary endpoint.
Instill Bio (TIL) shares were more than 46% higher after the company said it has appointed Jamie Freedman as chief medical officer.
Black Spade Acquisition II (BSII) stock was up 16% after the blank check company said late Friday its shareholders approved a pending business combination with The Generation Essentials Group.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.